Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank-check company formed to pursue an acquisition in the pharmaceutical and domestic drug manufacturing sector. The SPAC, a second vehicle under the Drugs Made In America franchise, filed a Form 10-Q with the Securities and Exchange Commission on November 18, 2025, indicating it remains in the target-search phase of its lifecycle. The company's investment mandate centers on the U.S. pharmaceutical supply chain and drug development industry, reflecting continued investor interest in domestically oriented life-sciences deal flow. Sign up on SpacDesk for full sponsor details, IPO vintage data, and real-time filing alerts on DMII and hundreds of other active SPACs.